Article
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2005
Corless Christopher L, Schroeder Arin, Griffith Diana, Town Ajia, McGreevey Laura, Harrell Patina, Shiraga Sharon, Bainbridge Troy, Morich Jason, Heinrich Michael C
Abstract excerpt
PURPOSE: Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib. A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro. Little is known of the other types of PDGFRA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.